Format

Send to

Choose Destination
Am J Obstet Gynecol. 2015 Apr;212(4):485.e1-485.e10. doi: 10.1016/j.ajog.2014.10.1097. Epub 2014 Oct 30.

17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.

Author information

1
Department of Obstetrics and Gynecology, Hôpital Mère-Enfant, Nantes, France.
2
Department of Obstetrics and Gynecology, Hôpital Nord, Marseille, France.
3
Department of Obstetrics and Gynecology, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpital Antoine Béclère, Université Paris Sud, Faculté de Médecine Paris XI, Paris, France.
4
Department of Obstetrics and Gynecology, Hôpital Morvan, Brest, France.
5
Department of Obstetrics and Gynecology, Hôpital Jeanne de Flandre, Lille, France.
6
Department of Obstetrics and Gynecology, Hôpital Bretonneau, Tours, France.
7
Department of Obstetrics and Gynecology, Hôpital Paul de Viguier, Toulouse, France.
8
Department of Obstetrics and Gynecology, Centre Médico-Chirurgical Obstetrical, Schiltigheim, France.
9
Department of Obstetrics and Gynecology, Hôpital Hautepierre, Strasbourg, France.
10
Department of Obstetrics and Gynecology, Hôpital de La Conception, Marseille, France.
11
Department of Clinical Research, Ile-de-France, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
12
Department of Biostatistics, Hôpital Saint-Louis, Paris Diderot University, and Institut National de la Santé et de la Recherche Médicale, Paris, France.
13
Department of Obstetrics and Gynecology, Hôpital Poissy-Saint Germain, Versailles-Saint Quentin University, Versailles, France. Electronic address: prozenberg@chi-poissy-st-germain.fr.

Abstract

OBJECTIVE:

The objective of the study was to evaluate the efficacy of 17 alpha-hydroxyprogesterone caproate (17OHP-C) in prolonging gestation in patients with a short cervix and other risk factors for preterm delivery, such as previous preterm birth, cervical surgery, uterine anomalies, or prenatal diethylstilbestrol (DES) exposure.

STUDY DESIGN:

This open-label, multicenter, randomized controlled trial included asymptomatic singleton pregnancies from 20(+0) through 31(+6) weeks of gestation with a cervical length less than 25 mm and a history of preterm delivery or cervical surgery or uterine malformation or prenatal DES exposure. Randomization assigned them to receive (or not) 500 mg of intramuscular 17OHP-C weekly until 36 weeks. The primary outcome was time from randomization to delivery.

RESULTS:

After enrolling 105 patients, an interim analysis demonstrated the lack of efficacy of 17OHP-C in prolonging pregnancy. The study was discontinued because of futility. The groups were similar for maternal age, body mass index, parity, gestational age at inclusion, history of uterine anomalies, DES syndrome, previous preterm delivery or midtrimester abortion, and cervical length at randomization. The enrollment-to-delivery interval did not differ between patients allocated to 17OHP-C (n = 51) and those allocated to the control group (n = 54) (median [interquartile range] time to delivery: 77 [54-103] and 74 [52-99] days, respectively). The rate of preterm delivery less than 37 (45% vs 44%, P > .99), less than 34 (24% vs 30%, P = .51), or less than 32 (14% vs 20%, P = .44) weeks was similar in patients allocated to 17OHP-C and those in the control group.

CONCLUSION:

17OHP-C did not prolong pregnancy in women with singleton gestations, a sonographic short cervix, and other risk factors of preterm delivery (prior history, uterine malformations, cervical surgery, or prenatal DES exposure).

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00331695.

KEYWORDS:

17 alpha-hydroxyprogesterone caproate; cervical length; prematurity; preterm birth; preterm labor; progesterone

Comment in

PMID:
25448515
DOI:
10.1016/j.ajog.2014.10.1097
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center